| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Laropiprant (aslo known as MK-0524; Cordaptive) is a novel, potent, selective DP [prostaglandin D2 (PGD2) receptor (DP)] receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively. Laropiprant, which was formerly prescribed in conjunction with niacin to lower blood cholesterol (LDL and VLDL), is no longer in production because of an increase in adverse effects that outweigh any cardiovascular benefits. The U.S. Food and Drug Administration (FDA) sent a "not approved" letter for Cordaptive on April 28, 2008. On July 3, 2008, the European Medicines Agency (EMA) approved Tredaptive. On January 11, 2013, Merck & Co. Inc. declared that they were discontinuing the medication globally due to suggestions from European regulators.
| Targets |
DP ( Ki = 0.57 nM ); TP Receptor ( Ki = 2.95 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
Laropiprant (100-100 mg/kg; intravenous and oral; male) Sprague-Dawley rats) show positive pharmacokinetic characteristics. [3]. An analysis of pharmacokinetics in male Sprague-Dawley rats [3] The dosage by route (mg/kg) AUC0-∞ (μM·hr) Clp (mL/min/kg) Vdss (L/kg) T1/2 (hour) PO 5 96.0 2.1 0.9 7.6 PO 1 22.7 1.9 0.7 7.4 The dosage by route (mg/kg) AUC0-∞ (μM·hr) Cmax (micrometer) Tmax in hours F(%) IV 5 15.6 1.2 52.6 /
|
|
| Cell Assay |
Vena8Fluoro+ Biochips are coated with collagen (200 µg/mL) at 4°C for an entire night. After that, they are blocked for 30 minutes at room temperature using bovine serum albumin (10 µg/mL), and then they are cleaned. After being collected in sodium citrate, 1 µM of 3, 3-dihexyloxacarbocyanine iodide is incubated for 10 minutes in the dark with whole blood. Ten minutes prior to the onset of perfusion, PGD2 (30 nM), BW245c (3 nM), and the DP antagonist BWA868c or Laropiprant (1 µM) are added. In an additional series of tests, whole blood is exposed to 30 minutes of treatment with either niacin (3 mM), acetylsalicylic acid (1 mM), or laropiprant (1 µM and 10 µM). A final concentration of 1 mM of CaCl2 is added two minutes prior to the perfusion over the chip coated in collagen. The shear rate at which perfusion occurs is 30 dynes cm^2. The formation of thrombus is noted. DucoCell analysis software is used for computerized image analysis, where the area covered by the thrombus is computed. Percentage of the area covered in a control sample is used to express data[2].
|
|
| References |
|
| Molecular Formula |
C21H19CLFNO4S
|
|---|---|
| Molecular Weight |
435.89600
|
| Exact Mass |
435.07
|
| Elemental Analysis |
C, 57.87; H, 4.39; Cl, 8.13; F, 4.36; N, 3.21; O, 14.68; S, 7.35
|
| CAS # |
571170-77-9
|
| Related CAS # |
Laropiprant sodium; 572874-50-1
|
| Appearance |
Solid powder
|
| SMILES |
CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F
|
| InChi Key |
NXFFJDQHYLNEJK-CYBMUJFWSA-N
|
| InChi Code |
InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
|
| Chemical Name |
2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid
|
| Synonyms |
MK-0524; Laropiprant; MK0524; MK 0524; Trade name: Cordaptive; Tredaptive
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~87 mg/mL (199.6 mM)
Ethanol: ~87 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2941 mL | 11.4705 mL | 22.9410 mL | |
| 5 mM | 0.4588 mL | 2.2941 mL | 4.5882 mL | |
| 10 mM | 0.2294 mL | 1.1471 mL | 2.2941 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01126073 | Completed | Drug: Niacin/laropiprant Drug: Placebo |
Coronary Heart Disease | University Medical Centre Ljubljana |
September 2010 | Phase 4 |
| NCT00485758 | Completed | Drug: ER niacin/laropiprant Drug: Comparator : placebo (unspecified) |
Diabetes Mellitus Type 2 | Merck Sharp & Dohme LLC | July 2007 | Phase 3 |
| NCT01451619 | Completed | Drug: Laropiprant Drug: Placebo for Laropiprant |
Rosacea | Merck Sharp & Dohme LLC | November 2011 | Phase 1 |
| NCT00536510 | Completed | Drug: Comparator: placebo Drug: laropiprant/niacin (MK0524A) |
Hypercholesterolemia Hyperlipidemia |
Merck Sharp & Dohme LLC | April 2007 | Phase 3 |
| NCT01321034 | Completed | Drug: Niacin/Laropiprant | Hypercholesterolemia | Instituto Aragones de Ciencias de la Salud |
October 2011 | Phase 4 |
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
